Table of Contents

State/Territory Name: Minnesota

State Plan Amendment (SPA) #: 17-0004

This file contains the following documents in the order listed:

- 1) Approval Letter
- 2) CMS 179 Form/Summary Form (with 179-like data)
- 3) Approved SPA Pages

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-14-26 Baltimore, Maryland 21244-1850



Center for Medicaid and CHIP Services

Disabled and Elderly Health Programs Group

April 12, 2017

Ms. Ann Berg
Deputy Medicaid Director
Minnesota Department of Human Services
P.O. Box 64998
St. Paul, MN 55164-0998

Dear Ms. Berg:

We have reviewed Minnesota's State Plan Amendment (SPA) 17-0004, Prescribed Drugs, received in the Chicago Regional Office on February 2, 2017. This amendment proposes to update the state plan to include utilization from participating MCOs for supplemental drug rebates for direct-acting antivirals for the treatment of hepatitis C.

Based on the information provided, we are pleased to inform you that, consistent with the regulations at 42 CFR 430.20, SPA 17-0004 is approved with an effective date of January 1, 2017. A copy of the signed CMS-179 form, as revised, as well as the pages approved for incorporation into the Minnesota state plan will be forwarded by the Chicago Regional Office.

If you have any questions regarding this amendment, please contact Lisa Ferrandi at (410) 786-5445 or lisa.ferrandi@cms.hhs.gov.

Meagan T. Khau
Deputy Director
Division of Pharmacy

CC: Ruth Hughes, ARA, CMS, Chicago Regional Office Sandra Porter, CMS, Chicago Regional Office Sean Barrett, Minnesota Department of Human Services

DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR MEDICARE & MEDICAID SERVICES	•	FORM APPROVED OMB NO. 0938-0193
TRANSMITTAL AND NOTICE OF APPROVAL OF	1. TRANSMITTAL NUMBER:	2. STATE
STATE PLAN MATERIAL		,
FOR: CENTER FOR MEDICARE & MEDICAID SERVICES	17-04	Minnesota
•	3. PROGRAM IDENTIFICATION: TITLE XIX OF THE SOCIAL SECURITY ACT (MEDICAID)	
TO: REGIONAL ADMINISTRATOR	4. PROPOSED EFFECTIVE DATE	
CENTER FOR MEDICARE & MEDICAID SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES		
	January 1, 2017	
5. TYPE OF PLAN MATERIAL (Check One):		
□ NEW STATE PLAN □ AMENDMENT TO BE C	ONSIDERED AS NEW PLAN	X AMENDMENT
COMPLETE BLOCKS 6 THRU 10 IF THIS IS AN AME		ch amendment)
6. FEDERAL STATUTE/REGULATION CITATION:	7. FEDERAL BUDGET IMPACT:	
42 CFR § 440.120(a)	a. FFY '17 \$0	
A DACEDAVIA	b. FFY '18 \$0	
8. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT:	9. PAGE NUMBER OF THE SUPER	
Attachment 3.1-A, 46f Attachment 3.1-B, 45f	OR ATTACHMENT (If Applicable	p):
Attachment 5.1-B, 45f	Same	•
10. (33)		MP
10. SUBJECT OF AMENDMENT:		
Pharmacy: Multi-state Pooling Agreement		
11. GOVERNOR'S REVIEW (Check One):		
x GOVERNOR'S OFFICE REPORTED NO COMMENT	☐ OTHER, AS SPECI	RIED.
☐ COMMENTS OF GOVERNOR'S OFFICE ENCLOSED		TIDD.
☐ NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL		
12. SIGNATURE OF STATE AGENCY OFFICIAL:	16. RETURN TO:	
	Sean Barrett Minnesota Department of Human Services Federal Relations Unit	
	PO Box 64983	
to demand the second of the se	St. Paul, MN 55164-0983	ASSESSED ASSESSED AND STATE ASSESSED AND STATE OF THE STA
13. TYPED NAME:		
Ann Berg 14, TITLE:		
Deputy Medicaid Director		
15. DATE SUBMITTED:		
February 2, 2017		
LEUS DE LE LES SESTEMBRES DE LE CONTROL DE L		
17. DATE RECEIVED:	18. DATE APPROVED:	
February 2, 2017	April 12,	2017
PLAN APPROVED - ONI		
19. EFFECTIVE DATE OF APPROVED MATERIAL:	20. SIGNATURE OF REGIONAL OF	
January 1, 2017		/s/
21. TYPED NAME:	22. TITLE:	1
Ruth A. Hughes 23. REMARKS:	Associate Regional A	amınıstrator
23. ICHANICAS,		
	,	
		· ·

STATE: MINNESOTA ATTACHMENT 3.1-A

Effective: January 1, 2017 Page 46f

TN: 17-04

Approved: 4-12-17

Supersedes: 13-10 (13-02, 12-19, 08-01, 05-09, 04-09, 03-36)

12.a. Prescribed drugs. (continued)

Prior Authorization:

A. The following requirements, found in §1927(d)(5) of the Act, are met:

- The prior authorization program provides a response by telephone or other telecommunication device within 24 hours of a request.
- The prior authorization program provides for the dispensing of at least a 72-hour supply of a covered drug in an emergency situation (except for those drugs that are excluded or restricted from coverage, as noted above).
- B. Prior authorization, for a period of not more than 180 days, may automatically be required for drugs approved by the FDA on or after July 1, 2005. The 180-day period begins no later than the first day that a drug is available for shipment to pharmacies within Minnesota. The Department's Drug Formulary Committee will establish general authorization criteria to be used during the 180-day period.
- C. Based on the requirements in §1927, the State has the following policies for the supplemental drug rebate program for Medicaid recipients:
 - 1. CMS has authorized the State of Minnesota to enter into the Michigan Multi-State Pooling Agreement (MMSPA) also referred to as the National Medicaid Pooling Initiative (NMPI) for drugs provided to Medicaid beneficiaries. The NMPI Supplemental Rebate Agreement (SRA) and the amendment to the SRA submitted to CMS on April 30, 2004 have been authorized for pharmaceutical manufacturers' existing agreements through their current expiration dates. The updated NMPI SRA effective for January 1, 2017, has been authorized for renewal and new agreements with pharmaceutical manufacturers for drugs provided to Medicaid beneficiaries.
 - 2. Supplemental drug rebates received by the State in excess of those required under the national drug rebate agreement will be shared with the Federal government on the same percentage basis as applied under the national drug rebate agreement.
 - 3. Manufacturers with supplemental rebate agreements are allowed to audit utilization data.

STATE: MINNESOTA ATTACHMENT 3.1-B

Effective: January 1, 2017 Page 45f

TN: 17-04

Approved: 4-12-17

Supersedes: 13-10 (13-02, 12-19, 08-01, 05-09, 04-09, 03-36)

12.a. Prescribed drugs. (continued)

Prior Authorization:

A. The following requirements, found in §1927(d)(5) of the Act, are met:

- The prior authorization program provides a response by telephone or other telecommunication device within 24 hours of a request.
- The prior authorization program provides for the dispensing of at least a 72-hour supply of a covered drug in an emergency situation (except for those drugs that are excluded or restricted from coverage, as noted above).
- B. Prior authorization, for a period of not more than 180 days, may automatically be required for drugs approved by the FDA on or after July 1, 2005. The 180-day period begins no later than the first day that a drug is available for shipment to pharmacies within Minnesota. The Department's Drug Formulary Committee will establish general authorization criteria to be used during the 180-day period.
- C. Based on the requirements in §1927, the State has the following policies for the supplemental drug rebate program for Medicaid recipients:
 - 1. CMS has authorized the State of Minnesota to enter into the Michigan Multi-State Pooling Agreement (MMSPA) also referred to as the National Medicaid Pooling Initiative (NMPI) for drugs provided to Medicaid beneficiaries. The NMPI Supplemental Rebate Agreement (SRA) and the amendment to the SRA submitted to CMS on April 30, 2004 have been authorized for pharmaceutical manufacturers' existing agreements through their current expiration dates. The updated NMPI SRA effective for January 1, 2017, has been authorized for renewal and new agreements with pharmaceutical manufacturers for drugs provided to Medicaid beneficiaries.
 - 2. Supplemental drug rebates received by the State in excess of those required under the national drug rebate agreement will be shared with the Federal government on the same percentage basis as applied under the national drug rebate agreement.
 - 3. Manufacturers with supplemental rebate agreements are allowed to audit utilization data.